DISCOVERY OF NOVEL TARGETS FOR POST-TRAUMATIC HEADACHE
发现创伤后头痛的新靶标
基本信息
- 批准号:10685784
- 负责人:
- 金额:$ 42.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-15 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAdverse effectsAffectAfferent NeuronsAnatomyBehaviorBehavioralCervicalChronicClinical ResearchColonDataDependovirusDevelopmentExhibitsFOS ProteinFaceFemaleFluoro-GoldGene ExpressionGenesGenetic TranscriptionGoalsHeadacheHigh PrevalenceHumanHypersensitivityIn Situ HybridizationIndividualKnowledgeLabelLiverLungMaintenanceMechanicsMediatingMembrane ProteinsMigraineMolecularMusMuscleNTN1 geneNeuronsNeuropeptidesPathogenesisPathway interactionsPatientsPeripheralPersonsPharmaceutical PreparationsPost-Traumatic HeadachesPosterior Horn CellsProceduresProductivityProteinsQuality of lifeResolutionStructure of trigeminal ganglionTherapeuticTimeTissuesTracerTraumaUp-RegulationVoltage-Gated Potassium Channelabuse liabilityaxon guidancebasebehavioral sensitizationbehavioral studycandidate identificationcommon symptomdrug discoveryexperienceexperimental studyfollow-upknock-downlarge-conductance calcium-activated potassium channelsmalemild traumatic brain injurymouse modelnetrin receptornoveloverexpressionpain scorepersistent symptompituitary adenylate cyclase activating polypeptidepreclinical studyreceptorscreeningside effectsingle-cell RNA sequencingsmall hairpin RNAtargeted treatmenttranscriptome
项目摘要
Project Summary/Abstract
Post-traumatic headache (PTH) is one of the most common and persistent symptoms following mild traumatic
brain injury (mTBI), which affects 50 million people every year. Despite being highly prevalent and debilitating,
chronic PTH remains poorly understood and with limited treatment options.
Both clinical and preclinical studies indicate that PTH may result from the prolonged sensitization of
peripheral dural afferent neurons. To identify molecules that are responsible for dural afferent sensitization in
PTH, we performed single cell RNA sequencing of dural afferent neurons to reveal mTBI-induced changes of
gene transcription in an unbiased manner. We have identified 3 genes that are significantly upregulated 7 days
after mTBI: 1) O95185, which encodes the netrin receptor UNC5C; 2) Q9NS66, which encodes the
neuropeptide phoenixin receptor GPR173; and 3) Q9Y691, which encodes KCNMB2, the 2 subunit of Ca2+-
and voltage-gated K+ channels of large conductance (BK channels).
All three genes encode understudied membrane proteins that are expressed at moderate to high levels in
both mouse and human trigeminal ganglion (TG) neurons; whereas their expression in other peripheral tissues
are much lower. Notably, UNC5C and GPR173 levels are higher in TG tissues from migraine patients. In order
to determine whether these proteins are potential targets for peripherally-active drugs to treat PTH with
minimal abuse liability and other side effects, one needs a critical piece of information as to whether they are
functionally involved in PTH pathogenesis. We will address this knowledge gap in the present study.
First, we will use RNAScope in situ hybridization to assess mTBI-induced spatial and temporal changes of
UNC5C, GPR173 and KCNMB2 expression in primary afferent neurons. The results will allow us to predict: 1)
the dural afferent subtype(s) that are regulated by each candidate; 2) the period during which each candidate
likely contributes to the pathogenesis of PTH; and 3) whether they may be targets that are selective for PTH.
Secondly, we will knockdown UNC5C, GPR173 or KCNMB2 expression in primary afferent neurons by
transducing mice with adeno-associated viruses (AAVs) encoding shRNA against individual genes. We will
also overexpress individual proteins in primary afferent neurons via AAV-mediated transduction. We will then
investigate mTBI-induced behavioral and cellular changes in these mice with multiple endpoints. These studies
will reveal whether UNC5C, GPR173 or KCNMB2 regulate the chronification and/or the resolution of PTH-
related behaviors, and whether overexpression or knockdown of these proteins exhibit therapeutic benefit.
Successful completion of these aims will help us identify understudied proteins that are critical for the
development, maintenance and/or the resolution of PTH and are potential targets for peripherally-acting, non-
addictive PTH treatment with minimal side effects. This will provide preliminary data for subsequent R01
application to further in-depth mechanistic studies or for the initiation of a drug discovery project.
项目摘要/摘要
创伤后头痛(PTH)是继轻度创伤后最常见和持续的症状之一。
脑损伤(MTBI),每年影响5000万人。尽管这种疾病非常普遍,令人虚弱,
慢性甲状旁腺激素仍然知之甚少,治疗选择有限。
临床和临床前研究都表明甲状旁腺激素可能是由于
外周硬脑膜传入神经元。识别导致硬脑膜传入敏化的分子
PTH,我们进行了硬脑膜传入神经元的单细胞RNA测序,以揭示mTBI引起的
以公正的方式进行基因转录。我们已经确定了3个在7天内显著上调的基因
在mTBI之后:1)O95185,它编码Netrin受体unc5C;2)Q9NS66,它编码
3)编码钙离子-2亚单位KCNMB2的Q9Y691。
和大电导的电压门控K+通道(BK通道)。
这三个基因都编码未被研究的膜蛋白,这些蛋白在
小鼠和人三叉神经节(TG)神经元均有表达;而它们在其他外周组织中的表达
要低得多。值得注意的是,偏头痛患者的甘油三酯组织中UNC5C和GPR173水平较高。按顺序
确定这些蛋白质是否是外周活性药物治疗甲状旁腺激素的潜在靶点
为了将滥用责任和其他副作用降至最低,人们需要一条关键的信息来说明它们是否
在功能上参与甲状旁腺激素的发病。我们将在本研究中解决这一知识差距。
首先,我们将使用RNAScope原位杂交来评估mTBI诱导的神经元的空间和时间变化。
UNC5C、GPR173和KCNMB2在初级传入神经元中的表达。结果将使我们能够预测:1)
由每个候选人调节的硬脑膜传入亚型(S);2)每个候选人
可能与甲状旁腺激素的发病有关;3)它们是否是甲状旁腺激素的选择性靶点。
其次,我们将通过以下方式抑制初级传入神经元中UNC5C、GPR173或KCNMB2的表达
用编码针对个别基因的shRNA的腺相关病毒(AAVs)转导小鼠。我们会
也通过AAV介导的转导在初级传入神经元中过表达个别蛋白。到时候我们会的
研究mTBI在这些多终点小鼠中诱导的行为和细胞变化。这些研究
将揭示是否unc5C、GPR173或KCNMB2调节甲状旁腺素的时序和/或分辨率-
相关的行为,以及这些蛋白的过度表达或敲除是否显示出治疗益处。
成功完成这些目标将帮助我们确定未被研究的蛋白质,这些蛋白质对
开发、维护和/或解决PTH,并是外围行动、非
甲状旁腺激素成瘾性治疗,副作用最小。这将为后续的R01提供初步数据
应用于进一步深入的机制研究或启动药物发现项目。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YUQING CAO其他文献
YUQING CAO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YUQING CAO', 18)}}的其他基金
Mechanisms of migraine chronification and reversal
偏头痛的慢性化和逆转机制
- 批准号:
10660758 - 财政年份:2023
- 资助金额:
$ 42.83万 - 项目类别:
Regulation of Trigeminal Nociception by TRESK Channels
TRESK 通道对三叉神经伤害感受的调节
- 批准号:
9814892 - 财政年份:2019
- 资助金额:
$ 42.83万 - 项目类别:
Regulation of Trigeminal Nociception by TRESK Channels
TRESK 通道对三叉神经伤害感受的调节
- 批准号:
10404505 - 财政年份:2018
- 资助金额:
$ 42.83万 - 项目类别:
Regulation of Trigeminal Nociception by TRESK Channels
TRESK 通道对三叉神经伤害感受的调节
- 批准号:
9896858 - 财政年份:2018
- 资助金额:
$ 42.83万 - 项目类别:
FUNCTIONAL COUPLING BETWEEN VOLTAGE-GATED CA2 CHANNELS AND TRESK K+ CHANNELS
电压门控 CA2 通道和 Tresk K 通道之间的功能耦合
- 批准号:
8920176 - 财政年份:2014
- 资助金额:
$ 42.83万 - 项目类别:
VOLTAGE-GATED CALCIUM CHANNELS IN MIGRAINE PATHOPHYSIOLOGY
偏头痛病理生理学中的电压门控钙通道
- 批准号:
8871819 - 财政年份:2014
- 资助金额:
$ 42.83万 - 项目类别:
VOLTAGE-GATED CALCIUM CHANNELS IN MIGRAINE PATHOPHYSIOLOGY
偏头痛病理生理学中的电压门控钙通道
- 批准号:
9464567 - 财政年份:2014
- 资助金额:
$ 42.83万 - 项目类别:
VOLTAGE-GATED CALCIUM CHANNELS IN MIGRAINE PATHOPHYSIOLOGY
偏头痛病理生理学中的电压门控钙通道
- 批准号:
9025809 - 财政年份:2014
- 资助金额:
$ 42.83万 - 项目类别:
VOLTAGE-GATED CALCIUM CHANNELS IN MIGRAINE PATHOPHYSIOLOGY
偏头痛病理生理学中的电压门控钙通道
- 批准号:
9242082 - 财政年份:2014
- 资助金额:
$ 42.83万 - 项目类别:
VOLTAGE-GATED CALCIUM CHANNELS IN MIGRAINE PATHOPHYSIOLOGY
偏头痛病理生理学中的电压门控钙通道
- 批准号:
8759402 - 财政年份:2014
- 资助金额:
$ 42.83万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 42.83万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 42.83万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 42.83万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 42.83万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 42.83万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 42.83万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 42.83万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 42.83万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 42.83万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 42.83万 - 项目类别:
Discovery Grants Program - Individual














{{item.name}}会员




